Eli Lilly (LLY) shares hit an all-time high Wednesday after the 澳洲幸运5官方开奖结果体彩网:Food and Drug Administration (FDA) approved the drug maker's Zepbound injection to treat people who are obese or are overweight and also have weight-related medical proꩵblems, such as♚ hypertension and Type 2 diabetes.

The FDA had already approved the drug's active ingredient, known as tirzepatide, in May 2022 as a treatment for patients with Type 2 diabetes under the brand name Mounjaro.

The company said the approval was based on results from its 澳洲幸运5官方开奖结果体彩网:Phase 3 study, which showed that patients who took the highest dose of Zepbound for 72 weeks lost an average of 48 pounds, while those on the lowest dose lost an average of 34 pounds. It added that 1 in 3 of the high-dose patients lost more than 58 pounds.

"For decades, diet and exercise have been a go-to, but it's not uncommon for a person to have tried 20-30 times to lose weight with this approach. Research now shows that the body may respond to a calorie-deficit diet by increasing hunger and reducing feelings of fullness, making weight loss more difficult. Lilly is aiming to eliminate misperceptions about this disease and transform how it can be managed," said Dr. Leonard Glass, senior vice president of global medical affairs at Lilly Diabetes and Obesity.

The FDA's approval comes as demand has skyrocketed for treatments that can help patients lose weight, boosting sales for Eli Lilly and 澳洲幸运5官方开奖结果体彩网:Novo Nordisk (NVO), the maker of Ozempic and Wegovy.

Lilly indicated that Zepbound is expected to be on the market by the end of the year at a list price of $1,060 for a one-month supply.

Correction—Nov. 9, 2023: This൲ article has been corrected to clarify that Zepbound is expected to be on the market by the end of the year at a list price of $1,060 for a one-mon♔th supply.